For research use only. Not for therapeutic Use.
Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1).
| Catalog Number | I045096 |
| CAS Number | 1637677-22-5 |
| Synonyms | 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide |
| Molecular Formula | C23H22F5N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1 |
| InChIKey | MSGYSFWCPOBHEV-AWEZNQCLSA-N |
| SMILES | CC1=C(C(=NN1)C)C2=CN(N=C2)C3(CN(C3)C4=C(C=C(C(=C4)F)C(=O)NC(C)C(F)(F)F)F)CC#N |
| Reference | [1]. Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp). Patent WO2021076124A1. |
